
Paul Romness discusses OS Therapies' innovative approach to treating osteosarcoma and other solid tumors through gene-edited cancer immunotherapies.
Paul Romness, Chair, Chief Executive Officer & President of OS Therapies, a clinical-stage oncology company and leader in gene-edited, Listeria-based cancer immunotherapies developing targeted treatments for osteosarcoma and other solid tumors joins eHealth Radio and the Cancer Information & Health News Channels. Listen to interview with host Eric Michaels & guest Paul Romness discuss the following: To start, you bring a wealth of leadership experience to the table, and you are now guiding OS Therapies through an incredibly pivotal regulatory chapter. Could you share what personally drew you to this mission, and how your background shaped the company's laser-focus on tackling devastating, hard-to-treat solid tumors like osteosarcoma? OS Therapies is described as a leader in gene-edited, Listeria-based cancer immunotherapies. For our audience, how do you harness Listeria bacteria to trigger an immune response against solid tumors? Traditional therapies usually look for just one specific marker to target a cancer cell, but cancers can mutate to hide from them. OST-HER2 goes after three different markers instead. How does this triple-target approach prevent the cancer…
Host: Eric Michaels
Guest: Paul Romness
Organizations: OS Therapies
Products: OST-HER2
Places: osteosarcoma, solid tumors
Explore listener stats, chart rankings, contacts and more on the ehealth radio network podcast page.